ArticleCancer research communications2025

IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors.

John Powderly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.